XML 20 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814
Investment in Viking Therapeutics, Inc. (Details)
$ / shares in Units, $ in Thousands, shares in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 11 Months Ended
Jan. 01, 2016
USD ($)
May. 31, 2015
USD ($)
$ / shares
shares
Apr. 30, 2015
USD ($)
May. 31, 2014
USD ($)
program
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
May. 04, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Schedule of Equity Method Investments [Line Items]                      
Payments to acquire IPO shares             $ 9,000 $ 0      
Investment in Viking Therapeutics         $ 31,826   31,826     $ 0  
Note receivable from Viking Therapeutics         5,547   5,547     0  
Loss percentage recorded                 100.00%    
Gain on deconsolidation of Viking Therapeutics         0 $ 0 28,190 0      
Equity in net losses from Viking Therapeutics         (2,169) 0 (3,040) 0      
Net losses         224,539 1,280 248,857 4,969      
Viking's Assets and Liabilities [Abstract]                      
Cash and cash equivalents         93,770 180,663 93,770 180,663   160,203 $ 11,639
Other current assets         1,777   1,777     1,842  
Capitalized IPO expenses         0   0     2,268  
Total current assets         210,324   210,324     186,419  
Other assets         248   248     207  
Total assets         521,700   521,700     258,029  
Accounts payable         3,143   3,143     7,698  
Accrued liabilities         4,156   4,156     4,866  
Total current liabilities         16,253   16,253     22,779  
Total liabilities         229,519   229,519     233,621  
Viking                      
Schedule of Equity Method Investments [Line Items]                      
Number of programs licensed | program       5              
Contingencies for repayment of debt     $ 20,000                
Period after close of IPO when debt becomes due     1 year                
Viking's Assets and Liabilities [Abstract]                      
Cash and cash equivalents                   756  
Other current assets                   18  
Capitalized IPO expenses                   2,268  
Total current assets                   3,042  
Other assets                   1  
Total assets                   3,043  
Accounts payable                   2,211  
Accrued liabilities                   77  
Current portion of notes payable                   334  
Total current liabilities                   2,622  
Long-term portion of notes payable                   2,331  
Total liabilities                   $ 4,953  
Debt | Viking                      
Schedule of Equity Method Investments [Line Items]                      
Convertible loan facility       $ 2,500              
Interest accrual rate, less than       5.00%              
Repayment in equity percentage     200.00%                
Metabasis Therapeutics                      
Viking's Assets and Liabilities [Abstract]                      
Contingent liability change in amount         (3,200) $ (1,200) 1,900 $ 700      
Metabasis Therapeutics | Forecast                      
Viking's Assets and Liabilities [Abstract]                      
Contingent liability change in amount $ (2,600)                    
IPO | Viking                      
Schedule of Equity Method Investments [Line Items]                      
Ownership after close of IPO (percent)     49.90%                
Viking Therapeutics, Inc.                      
Schedule of Equity Method Investments [Line Items]                      
Investment in Viking Therapeutics                 $ 34,900    
Net losses         4,700   18,300        
Viking's Assets and Liabilities [Abstract]                      
Total assets         19,000   19,000        
Total liabilities         $ 5,700   $ 5,700        
Common Stock                      
Schedule of Equity Method Investments [Line Items]                      
IPO shares purchased by the Company (shares) | shares   1.1                  
Payments to acquire IPO shares   $ 9,000                  
IPO shares received pursuant to amended MLA (shares) | shares   3.7                  
Aggregate value of shares received under licensing agreement   $ 29,200                  
Equity interest in outstanding common stock of Viking (percent)         48.80%   48.80%        
Common Stock | Viking Therapeutics, Inc.                      
Schedule of Equity Method Investments [Line Items]                      
IPO share price (USD per share) | $ / shares   $ 8                  
Common Stock | Viking Therapeutics, Inc. | IPO                      
Schedule of Equity Method Investments [Line Items]                      
Shares issued in IPO (shares) | shares   3.5                  
IPO share price (USD per share) | $ / shares   $ 8                  
IPO aggregate offering price   $ 27,600                  
Common Stock Received Pursuant to Master License Agreement | Metabasis Therapeutics                      
Viking's Assets and Liabilities [Abstract]                      
Contingent liability change in amount         $ 500   $ 800        
Viking Therapeutics, Inc.                      
Schedule of Equity Method Investments [Line Items]                      
Note receivable from Viking Therapeutics         $ 5,500   $ 5,500   $ 5,500